Finerenone shows positive results for chronic kidney disease associated with T1D
What’s happening? Today, Bayer shared data from the phase 3 FINE-ONE clinical trial. These results, which were presented at the American Society of Nephrology Kidney Week in Houston, TX, showed that finerenone (Kerendia™/Firialta™) significantly reduces urine albumin-to-creatinine ratio (UACR), a measure of kidney damage, in people with chronic kidney disease (CKD) associated with type 1 […]
Two new trials investigating baricitinib to delay T1D
What’s happening? Earlier today, Eli Lilly and Company announced that they are launching two new clinical trials for baricitinib in type 1 diabetes (T1D). These phase 3 trials will investigate whether the drug can delay T1D onset or progression and will open for recruitment soon. Read on to learn more about the trials, why this […]
Q&A with Patti Columbe: A glimpse into her journey with Vertex’s manufactured islets
Breakthrough T1D had the pleasure of speaking with Patti Columbe, a participant in Vertex’s pivotal trial for the manufactured islet therapy zimislecel (formerly VX-880). Patti has been living with type 1 diabetes (T1D) for nearly 39 years. This is one of the most exciting T1D trials in terms of getting us closer to cures for […]
The inside scoop on the CATT1 clinical trial
Learn about the people making the CATT1 clinical trial happen, the science behind cadisegliatin for type 1 diabetes, and how to get involved.
Study: Patients willing to incur risks for benefits of novel T1D therapies
A new Breakthrough T1D-funded study finds that people with T1D and their caregivers are largely willing to try advanced new T1D therapies.
A new Breakthrough T1D publication is paving the way for beta cell replacement therapies
Breakthrough T1D’s newest publication outlines a roadmap for beta cell replacement therapies for type 1 diabetes.
New publication alert: Engineered islets are making insulin and avoiding immune detection in first person treated
Hypoimmune (HIP) islets are making insulin, without immunosuppressants, in the first person treated with type 1 diabetes.
Who is at risk for type 1 diabetes?
Although its exact causes are unknown, researchers have uncovered type 1 diabetes risk factors that increase a person's likelihood of developing the condition.
Everything you need to know about ADA 2025
Check out Breakthrough T1D's ADA 2025 coverage of cutting-edge T1D updates in cures, improving lives, and clinical adoption.
ADA 2025 Recap: Medical Affairs
Medical Affairs (+Research and Advocacy) Breakthrough T1D’s Medical Affairs program is bridging the gap between access to and adoption of therapies, treatments, drugs, and devices for T1D. To accomplish this goal, the Medical Affairs team is working on healthcare provider (HCP) education, development of clinical care guidelines, and clinical trial education and awareness. Breakthrough T1D’s […]
